Activity and Tolerability of Ibrutinib with Bendamustine/Rituximab for Relapsed/Refractory CLL/SLL


Activity and Tolerability of Ibrutinib with Bendamustine/Rituximab for Relapsed/Refractory CLL/SLL
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (2/13/14)
Brown JR et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: Final results of a Phase 1b study. Proc ASH 2013;Abstract 525.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at the UW Carbone Cancer Center in Madison, Wisconsin.